Comparing a new targeted drug to standard care for advanced HER2-positive colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a new drug called BL-M07D1 as a possible treatment for advanced colorectal cancer that has HER2-positive tumors. If you've already tried standard chemotherapy and it didn't work, this study compares the new drug to the doctor's chosen standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have colorectal cancer that has spread (metastatic) and has already been treated with standard chemotherapy (oxaliplatin, fluorouracil, irinotecan).
- Your tumor must test strongly positive for HER2 (a protein) — often called HER2 IHC 3+.
- You must be well enough to carry out daily activities (ECOG 0 or 1).
- You must have at least one tumor that can be measured on a scan.
- You must not have serious heart, lung, or other major health issues, and you must not have active infections like HIV or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests two different drug combinations for people with advanced bowel cancer that has a specific genetic change (RAS mutation) and has already been treated with one type of chemotherapy. The goal is to see if one combination works better than the other.
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
This trial tests a new drug called JSKN003 against the usual treatments for people with HER2-positive advanced colorectal cancer that has stopped responding to standard chemotherapy. It aims to see if the new drug can help shrink or control the cancer better than current options.
This study tests a new drug called TQB2102 for colorectal cancer that has HER2-positive tumors and has stopped responding to standard treatments. The drug targets HER2 to try to slow or stop cancer growth.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.